The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease
Year: 2022
Type: review
Abstract: Immunotherapy with antigen-specific T cells is a promising, targeted therapeutic option for patients with cancer as well as for immunocompromised patients with virus infections. In this review, we characterize and compare current manufacturing protocols for the generation of T cells specific to viral and non-viral tumor-associated antigens. Specifically, we discuss: (1) the different methodologies to expand virus-specific T cell and non-viral tumor-associated antigen-specific T cell products, (2) an overview of the immunological principles involved when developing such manufacturing protocols, and (3) proposed standardized methodologies for the generation of polyclonal, polyfunctional antigen-specific T cells irrespective of donor source. Ex vivo expanded cells have been safely administered to treat numerous patients with virus-associated malignancies, hematologic malignancies, and solid tumors. Hence, we have performed a comprehensive review of the clinical trial results evaluating the safety, feasibility, and efficacy of these products in the clinic. In summary, this review seeks to provide new insights regarding antigen-specific T cell technology to benefit a rapidly expanding T cell therapy field.
Source: Molecular Therapy
Authors: Amy B. Hont, Allison B. Powell, Danielle K. Sohai, Izabella K. Valdez, Maja Stanojevic, Ashley E. Geiger, Kajal Chaudhary, Ehsan Dowlati, Catherine M. Bollard, Conrad Russell Y. Cruz
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,900
Funder: National Cancer Institute
OpenAlex ID: W4210825610
